Summary
The feasibility of combining cladribine with cyclophosphamide and prednisone in the management of indolent lymphoid malignancies was determined. Nineteen patients [nine chronic lymphocytic leukaemia (CLL), seven non-Hodgkin’s lymphoma (NHL) and three macroglobulinaemia (M))] received cladribine 0.1 mg kg–1 per day as a subcutaneous bolus injection on days 1–3 (up to 5 injections) with intravenous cyclophosphamide 500 mg m–2 on day 1 and oral prednisone 40 mg m–2 on days 1–5 at 4-weekly intervals up to a maximum of six courses. A total of 80 courses were given. Overall response rate was 88%, with four patients achieving a complete clinical and haematological response and 12 achieving a partial response. Neutropenia WHO grade 4 in two patients and WHO grade 3 infection in one patient were the limiting toxicities on treatment. During the follow-up, WHO grade ≥3 haematological complications occurred in five patients and WHO grade ≥3 non-haematological complications in five patients. There were no treatment-related deaths. This study demonstrates the feasibility of the cladribine/cyclophosphamide/prednisone (CCP) combination that appears highly active and safe in the management of indolent lymphoid malignancies.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Betticher, D. C., Fey, M. F., Rabaglio, M., Cerny, T., Hess, U., Meier, V., Stalder, M. & Zulian, G. (1993). Cladribine and severe myelotoxicity. Lancet 342: 1369
Betticher, D. C., Fey, M. F., von Rohr, A., Tobler, A., Jenzer, H., Gratwohl, A., Lohri, A., Pugin, P., Hess, U., Pagani, O., Zulian, G. & Cerny, T. (1994). High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 5: 57–64.
Betticher, D. C., Zucca, E., von Rohr, A., Egger, T., Radford, J. A., Ambrosetti, A., Burki, K., Rufener, B., Schmitz, S. F. & Cerny, T. (1996). 2-Chlorodeoxyadenosine (2CdA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin’s lymphoma. Ann Oncol 7: 793–799.
Beutler, E. (1992). Cladribine. Lancet 340: 952–956.
Cheson, B. D. (1995). Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13: 2431–2448.
Danhauser, L., Plunkett, W., Keating, M. & Cabanillas, F. (1986). 9-β-D-arabinofuranosyl-2-fluoro-adenine 5′-monophosphate pharmocokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18: 145–152.
Delannoy, A., Martiat, P., Gala, J. L., Deneys, V., Ferrant, A., Bosly, A., Scheiff, J. M. & Michaux, J. L. (1995). 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 9: 1130–1135.
Dimopoulos, M. A., Kantarjian, H., Estey, E., O’Brien, S., Estex, E., Delasalle, K., Keating, M. J., Freireich, E. J. & Alexanian, R. (1993). Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118: 195–198.
French cooperative group on chronic lymphocytic leukemia (1986). Effectiveness of CHOP regimen in advanced untreated chronic lymphocytic leukemia. Lancet 327: 1346–1349.
Hickish, T., Serafinowski, P., Cunningham, D., Oza, A., Dorland, E., Judson, I., Millar, B. C., Lister, T. A. & Roldan, A. (1993). 2′-chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 67: 139–143.
Hoffman, M., Tallman, M. S., Hakimian, D., Janson, D., Hogan, D., Variakogis, D., Kuzel, T., Gordon, L. I. & Rai, K. (1994). 2-chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin’s lymphoma. J Clin Oncol 12: 788–792.
Hosek, B., Bohacek, J. & Sikulova, J. (1991). The effect of cyclophosphamide and gamma irradiation on adenosine deaminase and purine nucleoside phosphorylase in mice. Life Sci 49: 1403–1407.
Juliusson, G. & Liliemark, J. (1993). High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 11: 679–689.
Juliusson, G. & Liliemark, J. (1996). Long term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 7: 373–379.
Juliusson, G., Elmhorn-Rosenborg, A. & Liliemark, J. (1992). Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 327: 1056–1061.
Juliusson, G., Christiansen, I., Hansen, M. M., Johnson, S., Kimby, E., Elmhorn-Rosenborg, A. & Liliemark, J. (1996). Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 14: 2160–2166.
Kaplan, H. S. & Meier, P. (1958). Nonparametric estimation from incomplete observations. Am J Stat Assoc 53: 457–481.
Kawasaki, H., Carrera, C. J., Piro, L. D., Saven, A., Kipps, T. J. & Carson, D. A. (1993). Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81: 597–601.
Kay, A. C., Saven, A., Carrerra, C. J., Carson, D. A., Beutler, E. & Piro, L. D. (1992). 2-chlorodeoxyadenosine in low grade lymphoma. J Clin Oncol 10: 371–377.
Liliemark, J., Albertioni, F., Hassan, M. & Juliusson, G. (1992). On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 10: 1514–1518.
Lister, T., Cullen, M. H., Beard, M. E., Brearley, R. L., Whitehouse, J. M., Wrigley, P. F., Stansfeld, A. G., Sutcliffe, S. B., Malpas, J. S. & Crowther, D. (1978). Comparison of combined and single-agent chemotherapy in non-Hodgkin’s lymphoma of favorable histological type. Br Med J 1: 533–537.
Nagourney, R. A., Evans, S. S., Messenger, J. C., Zhuang, S. u. Y. & Weisenthal, L. M. (1993). 2-chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer 67: 10–14.
O’Brien, S., Kantarjian, H., Estey, E., Koller, C., Robertson, B., Beran, M., Andreef, M., Pierce, S. & Keating, M. (1994). Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine. N Engl J Med 330: 319–322.
O’Brien, S., Kantarjian, H. & Keating, M. (1996). Purine analogs in chronic lymphocytic leukemia and Waldenström macroglobulinemia. Ann Oncol 7(suppl. 6) 27–33.
Piro, L. D., Carrera, C. J., Carson, D. A. & Beutler, E. (1990). Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322: 1117–1121.
Robertson, L. E., Chubb, S., Meyn, R. E., Story, M., Ford, R., Hittelman, W. N. & Plunkett, W. (1993). Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-d-arabinosyl-2-fluoroadenine. Blood 81: 143–150.
Rosenberg, A. S. (1985). The low-grade non-Hodgkin’s lymphomas: challenges and opportunities. J Clin Oncol 3: 299–310.
Saven, A. & Piro, L. D. (1994). 2-chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 120: 784–791.
Saven, A., Carrera, C. J., Carson, D. A., Beutler, E. & Piro, L. D. (1992). 2-chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80: 587–592.
Saven, A., Emanuele, S., Kosty, M., Koziol, J., Ellison, D. & Piro, L. (1995). 2-chlorodeoxyadenosine activity in patients with untreated indolent non-Hodgkin’s lymphoma. Blood 86: 1710–1716.
Saven, A., Lee, T., Kostly, M. & Piro, L. (1996). Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin’s lymphoma. J Clin Oncol 14: 2139–2144.
Seymour, J. F., Kurzrock, R., Freireich, E. J. & Estey, E. H. (1994). 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 83: 2906–2911.
Tefferi, A., Witzig, T. E., Reid, J. M., Chin-Yiang, L. & Ames, M. M. (1994). Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia and low-grade lymphoma. J Clin Oncol 12: 569–574.
Velasquez, W. S., Cabanillas, F., Salvador, P., McLaughlin, P., Fridrik, M., Tucker, S., Jagannath, S., Hagemesiter, F. B., Redman, J. R., Swan, F. & Barlogie, B. (1988). Effective salvage therapy for lymphoma with cisplatine in combination with high-dose ara-C and dexamethasone (DHAP). Blood 71: 117–122.
Young, R., Longo, D., Glatstein, E., Ihde, D. C., Jaffe, E. S. & De Vita, V. J. (1988). The treatment of indolent lymphomas; watchful waiting versus aggressive combined modality treatment. Sem Hematol 25: 11–16.
Zulian, G. B., Roux, E., Tiercy, J. M., Extermann, M., Diebold-Berger, S., Reymond, J. M., Helg, C., Zubler, R., Betticher, D. C., Alberto, P., Jeannet, M. & Chapuis, B. (1995). Transfusion associated graft-versus-host disease in a patient treated with cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis. Br J Haematol 89: 83–89.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Laurencet, F., Zulian, G., Guetty-Alberto, M. et al. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 79, 1215–1219 (1999). https://doi.org/10.1038/sj.bjc.6690195
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690195
This article is cited by
-
Waldenstrom macroglobulinemia: prognosis and management
Blood Cancer Journal (2015)
-
Bing–Neel syndrome: an illustrative case and a comprehensive review of the published literature
Journal of Neuro-Oncology (2010)
-
The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance
Current Oncology Reports (2007)
-
Waldenström macroglobulinemia
Current Treatment Options in Oncology (2004)
-
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia
Leukemia (2002)